| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/16/2023 | 12.15% | Piper Sandler | $13 → $9 | Maintains | Neutral |
| 09/29/2023 | 12.15% | Barclays | $14 → $9 | Maintains | Equal-Weight |
| 09/28/2023 | 37.07% | Bernstein | → $11 | Initiates Coverage On | → Outperform |
| 09/26/2023 | 74.45% | Cantor Fitzgerald | → $14 | Reiterates | Neutral → Neutral |
| 08/22/2023 | 74.45% | Cantor Fitzgerald | → $14 | Reiterates | Neutral → Neutral |
| 08/04/2023 | 61.99% | Morgan Stanley | $13 → $13 | Reiterates | Equal-Weight → Equal-Weight |
| 08/03/2023 | 61.99% | Morgan Stanley | $12 → $13 | Maintains | Equal-Weight |
| 06/30/2023 | 111.84% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
| 06/05/2023 | 111.84% | Canaccord Genuity | $14 → $17 | Maintains | Buy |
| 05/10/2023 | 74.45% | Barclays | → $14 | Initiates Coverage On | → Equal-Weight |
| 05/04/2023 | 49.53% | Morgan Stanley | $10 → $12 | Maintains | Equal-Weight |
| 05/03/2023 | 111.84% | TD Cowen | $15 → $17 | Maintains | Outperform |
| 05/03/2023 | 61.99% | Cantor Fitzgerald | $12 → $13 | Maintains | Neutral |
| 03/31/2023 | 86.92% | TD Cowen | $13 → $15 | Upgrades | Market Perform → Outperform |
| 01/05/2023 | 49.53% | Scotiabank | → $12 | Initiates Coverage On | → Sector Outperform |
| 11/16/2022 | 74.45% | Canaccord Genuity | $12 → $14 | Maintains | Buy |
| 08/17/2022 | -6.54% | Piper Sandler | $6 → $7.5 | Maintains | Neutral |
| 05/16/2022 | -25.23% | Piper Sandler | $13 → $6 | Maintains | Neutral |
| 05/06/2022 | 74.45% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 02/16/2022 | 398.44% | Canaccord Genuity | $45 → $40 | Maintains | Buy |
| 09/27/2021 | 460.75% | Canaccord Genuity | → $45 | Initiates Coverage On | → Buy |
| 08/04/2021 | 410.9% | Morgan Stanley | $45 → $41 | Maintains | Equal-Weight |
| 02/12/2021 | 460.75% | Morgan Stanley | $12 → $45 | Maintains | Equal-Weight |
| 02/11/2021 | 547.98% | Piper Sandler | $20 → $52 | Upgrades | Neutral → Overweight |
| 11/04/2020 | 49.53% | Morgan Stanley | $7 → $12 | Maintains | Equal-Weight |
| 11/03/2020 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 10/02/2020 | 86.92% | JP Morgan | → $15 | Upgrades | Neutral → Overweight |
| 10/01/2020 | 49.53% | Piper Sandler | $6 → $12 | Maintains | Overweight |
| 09/09/2020 | -12.77% | Morgan Stanley | → $7 | Initiates Coverage On | → Equal-Weight |
| 06/02/2020 | -37.69% | Cantor Fitzgerald | → $5 | Assumes | → Overweight |
| 03/09/2020 | -37.69% | Cantor Fitzgerald | → $5 | Assumes | → Overweight |
| 10/15/2019 | -0.31% | Piper Sandler | → $8 | Upgrades | Neutral → Overweight |
| 04/02/2019 | -0.31% | Stephens & Co. | → $8 | Downgrades | Overweight → Equal-Weight |
| 01/04/2019 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 11/12/2018 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 10/19/2018 | -19% | Cowen & Co. | → $6.5 | Initiates Coverage On | → Outperform |
What is the target price for Pacific Biosciences (PACB)?
The latest price target for Pacific Biosciences (NASDAQ: PACB) was reported by Piper Sandler on October 16, 2023. The analyst firm set a price target for $9.00 expecting PACB to rise to within 12 months (a possible 12.15% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacific Biosciences (PACB)?
The latest analyst rating for Pacific Biosciences (NASDAQ: PACB) was provided by Piper Sandler, and Pacific Biosciences maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Pacific Biosciences (PACB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
Is the Analyst Rating Pacific Biosciences (PACB) correct?
While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $13.00 to $9.00. The current price Pacific Biosciences (PACB) is trading at is $8.03, which is out of the analyst's predicted range.